Cancer treatment by combined inhibition of proteasome and telomerase activities
US7998938B2 · kind B2 · utility
12Cited by
4References
16Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Apr 14, 2006 |
| Grant date | Aug 16, 2011 |
| Priority date | — |
| Expiry date | Jul 25, 2027 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2310/3515
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A method and kit for inhibiting the proliferation of cancer cells are disclosed, based on a combination of a proteasome inhibitor and a telomerase inhibitor. When used in cancer therapy, the two compounds in combination enhance the anti-cancer treatment efficacy obtained with the proteasome inhibitor alone or the telomerase inhibitor alone. Preferably, efficacy is supraadditive or synergistic in nature relative to the combined effects of the individual agents, with minimal exacerbation of side effects.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.